Literature DB >> 7657608

A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.

Y Hsiung1, S H Elsea, N Osheroff, J L Nitiss.   

Abstract

In prokaryotic type II topoisomerases (DNA gyrases), mutations that result in resistance to quinolones frequently occur at Ser83 or Ser84 of the gyrA subunit. Mutations to Trp, Ala, and Leu have been identified, all of which confer high levels of quinolone resistance. Extensive segments of DNA gyrase are homologous to eukaryotic topoisomerase II, and Ser741 of yeast TOP2 is homologous to Ser83 of prokaryotic DNA gyrA. Introduction of the Ser741-->Trp mutation into yeast TOP2 confers resistance to 6,8-difluoro-7-(4'-hydroxyphenyl)-1-cyclopropyl- 4-quinolone-3-carboxylic acid (CP-115,953), a fluoroquinolone with substantial activity against eukaryotic topoisomerase II, whereas changing Ser741 to either Leu or Ala does not change sensitivity to quinolones. Interestingly, Ser741-->Trp in the yeast TOP2 also confers hypersensitivity to etoposide. Sensitivity to intercalating anti-topoisomerase II agents such as amsacrine is not changed by any of the three mutations. The topoisomerase II protein carrying the Ser741-->Trp mutation was overexpressed and purified. The purified mutant enzyme had enhanced levels of etoposide stabilized covalent complex as compared with the wild type enzyme and reduced cleavage with CP-115,953. Unlike the wild type enzyme, etoposide-stabilized cleavage is not readily reversible by heat. We suggest that Ser741 is near a binding site for both quinolones and etoposide and that the Ser741-->Trp mutation leads to a more stable ternary complex between etoposide, DNA, and the mutant enzyme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7657608     DOI: 10.1074/jbc.270.35.20359

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Replacement of ParC alpha4 helix with that of GyrA increases the stability and cytotoxicity of topoisomerase IV-quinolone-DNA ternary complexes.

Authors:  Emily S Pfeiffer; Hiroshi Hiasa
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity.

Authors:  Namiko Suda; Yasutomo Ito; Tsuneo Imai; Toyone Kikumori; Akihiko Kikuchi; Yukihiro Nishiyama; Shonen Yoshida; Motoshi Suzuki
Journal:  Nucleic Acids Res       Date:  2004-03-16       Impact factor: 16.971

Review 3.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

4.  Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.

Authors:  Nicole Stantial; Anna Rogojina; Matthew Gilbertson; Yilun Sun; Hannah Miles; Samantha Shaltz; James Berger; Karin C Nitiss; Sue Jinks-Robertson; John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-12       Impact factor: 11.205

5.  Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

Authors:  Michelle Sabourin; John L Nitiss; Karin C Nitiss; Kazuo Tatebayashi; Hideo Ikeda; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

6.  Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

Authors:  Anna T Rogojina; John L Nitiss
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

7.  A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.

Authors:  Thomas Gruger; John L Nitiss; Anthony Maxwell; E Lynn Zechiedrich; Peter Heisig; Siegfried Seeber; Yves Pommier; Dirk Strumberg
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II.

Authors:  E L Baldwin; A C Berger; A H Corbett; N Osheroff
Journal:  Nucleic Acids Res       Date:  2005-02-17       Impact factor: 16.971

9.  Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.

Authors:  Pan F Chan; Velupillai Srikannathasan; Jianzhong Huang; Haifeng Cui; Andrew P Fosberry; Minghua Gu; Michael M Hann; Martin Hibbs; Paul Homes; Karen Ingraham; Jason Pizzollo; Carol Shen; Anthony J Shillings; Claus E Spitzfaden; Robert Tanner; Andrew J Theobald; Robert A Stavenger; Benjamin D Bax; Michael N Gwynn
Journal:  Nat Commun       Date:  2015-12-07       Impact factor: 14.919

10.  Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.

Authors:  Dirk Strumberg; John L Nitiss; Jiaowang Dong; Jerrylaine Walker; Marc C Nicklaus; Kurt W Kohn; Jonathan G Heddle; Anthony Maxwell; Siegfried Seeber; Yves Pommier
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.